Tarsus Pharmaceuticals, Inc. Common Stock
TARS
$87.22
-3.92%
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class therapeutics, primarily in eye care, with its lead product XDEMVY (lotilaner ophthalmic solution) targeting Demodex blepharitis. The company is also advancing pipeline candidates for ocular rosacea (TP-04) and infectious disease prophylaxis (TP-05 for Lyme disease and malaria). As a niche player in the ophthalmic space, Tarsus has established a strong commercial foothold with XDEMVY, which has driven rapid revenue growth since its launch. The current investor narrative centers on the company's impressive revenue trajectory, expanding commercial execution, and the potential for pipeline catalysts, while also debating the sustainability of growth as competition and market penetration evolve.…
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
$87.22
TARS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tarsus Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $94.00 and implied upside of +7.8% versus the current price.
Average Target
$94.00
0 analysts
Implied Upside
+7.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $104
Analyst target range
The target price range spans from a low of $84.00 to a high of $104.00. The low target suggests a potential downside of 7.47%, possibly pricing in slower growth or competitive pressures, while the high target implies 14.56% upside, likely assuming continued strong commercial execution and pipeline success. The spread of $20 (about 22% of the average target) indicates moderate uncertainty. Recent institutional actions have been predominantly positive, with reaffirmations of Buy ratings from HC Wainwright, Oppenheimer, and Guggenheim, and no downgrades, reinforcing the bullish outlook.
Drowning in data?
Find the real signal!
Bulls vs Bears: TARS Investment Factors
Tarsus Pharmaceuticals presents a compelling bull case driven by exceptional revenue growth (106.87% YoY), high gross margins (94.2%), and strong analyst support (Strong Buy consensus). The bear case centers on premium valuation (trailing PS 7.58x), single-product dependence, and negative cash flow. Currently, the bull case has stronger evidence given the accelerating revenue trajectory and improving profitability, but the key tension is whether XDEMVY's growth can sustain the current valuation. If revenue growth decelerates or competition intensifies, the stock could face significant downside, while continued strong execution could drive further upside.
Bullish
- Exceptional Revenue Growth: Q1 2026 revenue surged 106.87% YoY to $162.05M, with sequential growth from $151.67M in Q4 2025 and $118.70M in Q3 2025, indicating accelerating adoption of XDEMVY. This rapid ramp demonstrates strong commercial execution and market acceptance.
- High Gross Margin: Gross margin for Q1 2026 was 94.2%, reflecting the premium pricing of XDEMVY and efficient manufacturing. This high margin provides significant operating leverage as revenue scales, supporting future profitability.
- Strong Analyst Sentiment: All 8 analysts rate TARS as Strong Buy (mean 1.0), with an average target of $94.00, implying 3.55% upside from the current price of $90.78. Recent reaffirmations from HC Wainwright, Oppenheimer, and Guggenheim reinforce the bullish outlook.
- Improving Profitability: Net loss narrowed dramatically from -$25.12M in Q1 2025 to -$6.97M in Q1 2026, with net margin improving from -32.07% to -4.30%. This trend suggests the company is approaching breakeven, with analysts projecting EPS of $10.33 for the next fiscal year.
Bearish
- Premium Valuation: Trailing PS ratio of 7.58x is elevated, though forward PS is 2.22x based on estimated revenue of $1.54B. If growth decelerates, the stock could face multiple compression, especially given the stock's 58.07% run over the past year.
- Dependence on Single Product: XDEMVY accounts for the vast majority of revenue, with product revenue of $145.39M in Q1 2026 out of total $162.05M. Any setback—such as competition, reimbursement issues, or safety concerns—would disproportionately impact the company.
- Uncertainty in Growth Sustainability: While growth is exceptional, the market for Demodex blepharitis may become saturated, and competition could emerge. The 52-week low of $48.20 shows the stock's volatility, and the current price near the high leaves limited margin of safety.
- Negative Cash Flow: Free cash flow TTM is -$31.54M, and the company is not yet profitable on a trailing basis. While the current ratio of 3.85 provides liquidity, continued cash burn could necessitate dilution if profitability is delayed.
TARS Technical Analysis
Tarsus Pharmaceuticals is in a strong uptrend, with the stock price at $90.78 as of September 4, 2026, up 58.07% over the past year. The current price is near the top of its 52-week range, sitting at approximately 99.2% of the high of $91.53, indicating robust momentum and bullish sentiment. This positioning near the highs suggests the market is rewarding the company's operational progress, though it also raises the risk of short-term overextension.
Beta
0.54
0.54x market volatility
Max Drawdown
-32.0%
Largest decline past year
52-Week Range
$48-$92
Price range past year
Annual Return
+53.3%
Cumulative gain past year
| Period | TARS Return | S&P 500 |
|---|---|---|
| 1m | +34.6% | -0.9% |
| 3m | +42.4% | +5.6% |
| 6m | +27.9% | +15.0% |
| 1y | +53.3% | +18.1% |
| ytd | +8.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TARS Fundamental Analysis
Tarsus has demonstrated exceptional revenue growth, with Q1 2026 revenue of $162.05 million, representing a 106.87% year-over-year increase from $78.34 million in Q1 2025. The sequential trend is also strong, with revenue rising from $151.67 million in Q4 2025 and $118.70 million in Q3 2025, indicating accelerating commercial adoption of XDEMVY. Product revenue of $145.39 million in Q1 2026, up from $78.34 million in the prior year quarter, underscores the core driver, while license and collaboration revenue of $16.67 million adds diversification.
Quarterly Revenue
$162054000.0B
2026-03
Revenue YoY Growth
+106.9%
YoY Comparison
Gross Margin
94.2%
Latest Quarter
Free Cash Flow
$-31539000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TARS Overvalued?
Given that Tarsus is not yet profitable on a trailing basis (net income of -$6.97 million in Q1 2026), the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio stands at 7.58x, while the forward PS ratio is not directly provided but can be estimated using analyst revenue estimates; with an estimated revenue of $1.54 billion for the next fiscal year, the forward PS is approximately 2.22x, implying the market expects substantial revenue growth. The gap between trailing and forward multiples reflects the market's anticipation of continued rapid expansion.
PE
-51.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-62.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Tarsus is not yet profitable, with a trailing net loss of -$6.97M in Q1 2026, though losses are narrowing. The company has a debt-to-equity ratio of 0.27, indicating manageable leverage, but negative free cash flow of -$31.54M TTM raises concerns about long-term capital needs. Revenue is heavily concentrated in XDEMVY, with product revenue of $145.39M in Q1 2026, making the company vulnerable to any disruption in that product's commercial success. Operating expenses remain high at $158.78M in Q1 2026, driven by SG&A of $136.43M, which could pressure margins if revenue growth slows.
